Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9737562 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9737048 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL2166333 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9736549 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9737427 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9736910 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9738506 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL3687100 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9739554 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9737848 | 0.95 | LMNA (0.37) | MPILMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0635051-B1 | INCREASING THE TREHALOSE CONTENT OF ORGANISMS BY TRANSFORMING THEM WITH COMBINATIONS OF THE STRUCTURAL GENES FOR TREHALOSE SYNTHASE | BTG INT LTD (GB) | 2004-06-23 | — | — | EP | claimed |
| EP-1356072-A2 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS AND SUBSEQUENT MODIFICATION OF URIDINE-5'-DIPHOSPHOSULFOQUINOVOSE (UDP-SQ) | MICHIGAN STATE UNIVERSITY (US) | 2003-10-29 | — | — | EP | claimed |
| WO-2002048706-A2 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS AND SUBSEQUENT MODIFICATION OF URIDINE-5'-DIPHOSPHOSULFOQUINOVOSE (UDP-SQ) | MICHIGAN STATE UNIVERSITY (US) | 2002-06-20 | — | — | WO | claimed |
| EP-0763132-B1 | ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY | ISOLAB INC (US) | 2001-01-24 | — | — | EP | claimed |
| WO-2026102337-A1 | ENPP1 FOR USE IN THE TREATMENT OF CALCIPHYLAXIS | BIOMARIN PHARMACEUTICAL INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260049294-A1 | ENPP1 Polypeptides and Methods of Using Same | UNIV YALE (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260041742-A1 | METHOD AND COMPOSITIONS FOR TREATMENT, AMELIORATION, AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) | UNIV YALE (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260015595-A1 | ENGINEERED GLYCOSYLTRANSFERASES AND STEVIOL GLYCOSIDE GLUCOSYLATION METHODS | TATE & LYLE SOLUTIONS USA LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260002136-A1 | ENGINEERED GLYCOSYLTRANSFERASES AND STEVIOL GLYCOSIDE GLUCOSYLATION METHODS | TATE & LYLE SOLUTIONS USA LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388882-A1 | COMPOSITIONS FOR TREATING ECTOPIC CALCIFICATION DISORDERS, AND METHODS USING SAME | UNIV YALE (US) | 2025-12-25 | — | — | US | disclosed |
| US-12454682-B2 | Engineered glycosyltransferases and steviol glycoside glucosylation methods | TATE & LYLE SOLUTIONS USA LLC (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2025042995-A9 | TREATMENT OF ENPP1 DEFICIENCY AND ABCC6 DEFICIENCY IN CHILDREN | INOZYME PHARMA, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-0617625-A1 | USE OF UDPG AS CANCER THERAPY RESCUE AGENT | BOEHRINGER MANNHEIM ITALIA S.p.A. (IT) | 1994-10-05 | — | — | EP | disclosed |
| WO-1994008563-A9 | NOVEL CLASS OF PHOSPHOCHOLINE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY | — | 1994-06-09 | — | — | WO | disclosed |
| WO-1993013779-A3 | USE OF UDPG AS CANCER THERAPY RESCUE AGENT | BOEHRINGER MANNHEIM ITALIA (IT) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993013779-A2 | USE OF UDPG AS CANCER THERAPY RESCUE AGENT | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-07-22 | — | — | WO | disclosed |
| EP-0506772-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A PHOSPHOSUGAR | PERSTORP AB (SE) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991009604-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A PHOSPHOSUGAR | PERSTORP AB (SE) | 1991-07-11 | — | — | WO | disclosed |
| WO-1991000867-A1 | 5'-DIPHOSPHOHEXOSE NUCLEOSIDE PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-01-24 | — | — | WO | disclosed |
| WO-1986003678-A1 | COMPOSITION AND METHOD FOR TREATMENT OF TUMORS WITH UDPG | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) | 1986-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002136-A1 | ENGINEERED GLYCOSYLTRANSFERASES AND STEVIOL GLYCOSIDE GLUCOSYLATION METHODS | UGGT1, UGCG, COASY | MPI 47/4885LMNA 3600/4885L3MBTL1 892/4885 |
| US-20250388882-A1 | COMPOSITIONS FOR TREATING ECTOPIC CALCIFICATION DISORDERS, AND METHODS USING SAME | ALPI, ENPP3, ALPP | MPI 1951/4885LMNA 4175/4885L3MBTL1 3794/4885 |
| US-20260015595-A1 | ENGINEERED GLYCOSYLTRANSFERASES AND STEVIOL GLYCOSIDE GLUCOSYLATION METHODS | UGGT1, COASY, GBA3 | MPI 20/4885LMNA 4011/4885L3MBTL1 1337/4885 |
| US-20260049294-A1 | ENPP1 Polypeptides and Methods of Using Same | ENPP1, ENPP3, PNP | MPI 521/4885LMNA 1872/4885L3MBTL1 235/4885 |
| US-12454682-B2 | Engineered glycosyltransferases and steviol glycoside glucosylation methods | UGGT1, GBA3, UGCG | MPI 50/4885LMNA 4401/4885L3MBTL1 2716/4885 |
| US-20260041742-A1 | METHOD AND COMPOSITIONS FOR TREATMENT, AMELIORATION, AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) | SOST, ALB, ENPP2 | MPI 2845/4885LMNA 3957/4885L3MBTL1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.